Neumune (HE2100) is a radiation countermeasure being developed by Hollis-Eden Pharmaceuticals for the treatment of acute radiation syndrome. The drug was introduced as a radiation countermeasure by, and is being co-developed with, the United States Armed Forces Radiobiology Research Institute. The chemical name for Neumune is androst-5-ene-3beta,17beta-diol or 5-androstenediol (AED), one of two androstenediols.
The clinical trials on rhesus monkeys have been succesful. According to the Hollis-Eden report, only 12.5% of the 40 Neumune-treated animals died versus 32.5% in the placebo group.[1]
On March 9, 2007, the radiation contract with Hollis-Eden had been cancelled by HHS on a technicality. According to HHS, "the product was no longer in the competitive range for the Request for Proposal". [2]
External links
- Neumune - Official Hollis-Eden Pharmaceuticals website
- New Scientist article on AED as an anti-radiation sickness drug